A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E ε4 allele

Table 2 Loci exhibiting pairwise linkage disequilibrium at p <= 0.05. Bold-faced loci indicate a combination detected at the α = 0.05 level in an AD stratum but not in the corresponding control stratum. These multi-locus combinations were used as models in LR analyses.

	Loci	D'	p-value		Loci	D'	p-value
*AD males*	lhcgr1/lhb1	0.576	0.029	*Control males*	lhcgr1/lhb3	1.000	0.019
	lhcgr1/lhb5	0.388	0.020		lhcgr1/lhb5	0.494	0.033
	lhcgr2/ *APOE*	1.000	0.002^a		lhcgr4/APOE	0.643	0.048
	lhcgr5/lhb2	0.305	0.023		lhcgr5/APOE	0.746	0.047
	lhcgr5/lhb4	0.293	0.033
	lhcgr5/lhb5	0.335	0.028
*AD females*	lhcgr2/APOE	0.520	0.032	*Control females*	lhcgr1/lhb1	0.415	0.004^b
	lhb3/ *APOE*	0.718	<0.0001^b		lhcgr1/APOE	0.281	0.031
					lhcgr2/APOE	0.315	0.007^b
*All AD*	lhcgr1/lhb1	0.465	0.017	*All Control*	lhcgr1/lhb1	0.352	0.006^c
	lhb3/ *APOE*	0.540	<0.0001^c		lhcgr1/lhb2	0.419	0.021
					lhcgr2/APOE	0.265	0.044
*All males*	lhcgr1/lhb1	0.387	0.004^a	*All females*	lhcgr1/lhb1	0.369	0.01^a
	lhcgr1/lhb2	0.301	0.047		lhcgr2/APOE	0.294	0.019
	lhcgr1/lhb3	0.365	0.009^a		lhb3/APOE	0.296	0.041
	lhcgr1/lhb4	0.312	0.038
	lhcgr1/lhb5	0.458	0.001^a
	lhcgr1/lhb6	0.323	0.028

^a significant at the corrected α = 0.0077 level (modified FDR) for the male dataset
^b significant at the corrected α = 0.0082 level (modified FDR) for the female dataset
^c significant at the corrected α = 0.0081 level (modified FDR) for the total dataset.

ISSN: 1471-2350